title: Influence of RANKL inhibition on immune system in the treatment of bone diseases.
abstract: Receptor activator of nuclear factor-kappaB ligand (RANKL) is essential for osteoclast differentiation, activation and survival. Recently, denosumab, a human monoclonal antibody to RANKL, has been tested in the treatment of osteoporosis. But the interactions between RANKL, receptor activator of nuclear factor-kappaB (RANK) and osteoprotegerin (OPG) are also involved in immune regulations in addition to bone metabolism. So, blocking RANKL could interplay with immune cells and have systemic effects. Here, we review biological data regarding potential consequences of RANKL blocking on the immune system.
authors.affiliation: Service de Rhumatologie, Hôpital Edouard Herriot, 5 place d'Arsonval, 69437 Lyon Cedex, France. afamedezine@hotmail.com
authors.forename: Anne
authors.initials: A
authors.lastname: Fouque-Aubert
authors.forename: Roland
authors.initials: R
authors.lastname: Chapurlat
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001168:Arthritis / Q000276:immunology; D001847:Bone Diseases / Q000276:immunology*; D016723:Bone Remodeling / Q000276:immunology; D016207:Cytokines / Q000276:immunology; D003713:Dendritic Cells / Q000276:immunology; D000069448:Denosumab; D004195:Disease Models, Animal; D006801:Humans; D008198:Lymph Nodes / Q000276:immunology; D009000:Monocytes / Q000276:immunology; D053245:RANK Ligand / Q000276:immunology* / Q000502:physiology / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D016207:Cytokines; D053245:RANK Ligand; C505688:TNFSF11 protein, human; D000069448:Denosumab